{"entity":{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","aka":[],"tldr":"Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.","summary":"Myung-Ju Ahn leads thoracic medical oncology at Samsung Medical Center and has been a principal or co-investigator on many of the pivotal NSCLC trials of the last decade, including osimertinib, lorlatinib, and checkpoint-inhibitor studies with large Korean enrolment. Her work spans EGFR resistance, ALK inhibitors, and head-and-neck immunotherapy.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn%20MJ%5BAuthor%5D%20Samsung%20Medical%20Center"}],"tags":["lung"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":["egfr","alk"],"drugs":["osimertinib","lorlatinib"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["crown"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Division of Hematology-Oncology; thoracic and head-and-neck medical oncology","institutionId":"samsung-medical-center","specialisms":["Lung cancer","Head and neck cancer","Targeted therapy","Immunotherapy","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn%20MJ%5BAuthor%5D%20Samsung%20Medical%20Center"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"},{"title":"Lorlatinib versus crizotinib in advanced ALK-positive NSCLC (CROWN)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2027187"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}]},"route":"/people/ahn-myung-ju/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/"}],"trial":[{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/"}],"paper":[{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"}],"company":[{"id":"kcsg","kind":"company","name":"Korean Cancer Study Group","route":"/companies/kcsg/"}]}}